Polymorphisms in mitochondrial genes and prostate cancer risk

Cancer Epidemiology Biomarkers and Prevention

Volumn 17, Issue 12, 2008, Pages 3558-3566

  Wang, Liang ^a   McDonnell, Shannon K ^a   Hebbring, Scott J ^a   Cunningham, Julie M ^a   St Sauver, Jennifer ^a   Cerhan, James R ^a   Isaya, Grazia ^a   Schaid, Daniel J ^a   Thibodeau, Stephen N ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CANCER RISK; CONTROLLED STUDY; DISEASE ASSOCIATION; FAMILIAL CANCER; GENE FREQUENCY; HAPLOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; MITOCHONDRIAL GENE; PRIORITY JOURNAL; PROSTATE CANCER; SINGLE NUCLEOTIDE POLYMORPHISM;

AGED; ALLELES; CASE-CONTROL STUDIES; GENES, MITOCHONDRIAL; GENETIC MARKERS; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HAPLOTYPES; HUMANS; LINKAGE DISEQUILIBRIUM; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSTATIC NEOPLASMS; RISK FACTORS;

EID: 57449096146     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-08-0434     Document Type: Article

References (42)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin 2008;58:71-96.
2. Chan JM, Stampfer MJ, Giovannucci EL. What causes prostate cancer? A brief summary of the epidemiology. Semin Cancer Biol 1998;8:263-73.
3. Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun MJ. Cancer statistics, 2003. CA Cancer J Clin 2003;53:5-26.
4. Hsing AW, Tsao L, Devesa SS. International trends and patterns of prostate cancer incidence and mortality. Int J Cancer 2000;85:60-7.
5. Langeberg WJ, Isaacs WB, Stanford JL. Genetic etiology of hereditary prostate cancer. Front Biosci 2007;12:4101-10.
6. Schaid DJ. The complex genetic epidemiology of prostate cancer. Hum Mol Genet 2004;13 Special:R103-21.
7. Polyak K, Li Y, Zhu H, et al. Somatic mutations of the mitochondrial genome in human colorectal tumours. Nat Genet 1998;20:291-3.
8. Singh KK. Mitochondrial dysfunction is a common phenotype in aging and cancer. Ann N Y Acad Sci 2004;1019:260-4.
9. Chen JZ, Gokden N, Greene GF, Mukunyadzi P, Kadlubar FF. Extensive somatic mitochondrial mutations in primary prostate cancer using laser capture microdissection. Cancer Res 2002;62:6470-4.
10. Petros JA, Baumann AK, Ruiz-Pesini E, et al. mtDNA mutations increase tumorigenicity in prostate cancer. Proc Natl Acad Sci U S A 2005;102:719-24.
11. Taylor RW, Turnbull DM. Mitochondrial DNA mutations in human disease. Nat Rev Genet 2005;6:389-402.
12. Navaglia F, Basso D, Fogar P, et al. Mitochondrial DNA D-loop in pancreatic cancer: somatic mutations are epiphenomena while the germline 16519 T variant worsens metabolism and outcome. Am J Clin Pathol 2006;126:593-601.
13. Mims MP, Hayes TG, Zheng S, et al. Mitochondrial DNA G10398A polymorphism and invasive breast cancer in African-American women. Cancer Res 2006;66:1880; author reply 1880-1.
14. Horton TM, Petros JA, Heddi A, et al. Novel mitochondrial DNA deletion found in a renal cell carcinoma. Genes Chromosomes Cancer 1996;15:95-101.
15. Habano W, Nakamura S, Sugai T. Microsatellite instability in the mitochondrial DNA of colorectal carcinomas: evidence for mismatch repair systems in mitochondrial genome. Oncogene 1998;17:1931-7.
16. Eng C, Kiuru M, Fernandez MJ, Aaltonen LA. A role for mitochondrial enzymes in inherited neoplasia and beyond. Nat Rev Cancer 2003;3:193-202.
17. Benn DE, Richardson AL, Marsh DJ, Robinson BG. Genetic testing in pheochromocytoma- and paraganglioma-associated syndromes. Ann N Y Acad Sci 2006;1073:104-11.
18. Sudarshan S, Linehan WM, Neckers L. HIF and fumarate hydratase in renal cancer. Br J Cancer 2007;96:403-7.
19. Canter JA, Kallianpur AR, Parl FF, Millikan RC. Mitochondrial DNA G10398A polymorphism and invasive breast cancer in African-American women. Cancer Res 2005;65:8028-33.
20. Booker LM, Habermacher GM, Jessie BC, et al. North American white mitochondrial haplogroups in prostate and renal cancer. J Urol 2006;175:468-73.
21. Verma M, Naviaux RK, Tanaka M, et al. Meeting report: mitochondrial DNA and cancer epidemiology. Cancer Res 2007;67:437-9.
22. Berry R, Schroeder JJ, French AJ, et al. Evidence for a prostate cancer-susceptibility locus on chromosome 20. Am J Hum Genet 2000;67:82-91.
23. Berry R, Schaid DJ, Smith JR, et al. Linkage analyses at the chromosome 1 loci 1q24-25 (HPC1), 1q42.2-43 (PCAP), and 1p36 (CAPB) in families with hereditary prostate cancer. Am J Hum Genet 2000;66:539-46.
24. Melton LJ III. History of the Rochester Epidemiology Project. Mayo Clin Proc 1996;71:266-74.
25. Oesterling JE, Jacobsen SJ, Chute CG, et al. Serum prostate-specific antigen in a community-based population of healthy men. Establishment of age-specific reference ranges. JAMA 1993;270:860-4.
26. Yeager M, Orr N, Hayes RB, et al. Genome-wide association study of prostate cancer identifies a second risk locus at 8q24. Nat Genet 2007; 39:645-9.
27. Saxena R, de Bakker PI, Singer K, et al. Comprehensive association testing of common mitochondrial DNA variation in metabolic disease. Am J Hum Genet 2006;79:54-61.
28. Carlson CS, Eberle MA, Rieder MJ, Yi Q, Kruglyak L, Nickerson DA. Selecting a maximally informative set of single-nucleotide polymorphisms for association analyses using linkage disequilibrium. Am J Hum Genet 2004;74:106-20.
29. Steemers FJ, Gunderson KL. Illumina, Inc. Pharmacogenomics 2005;6:777-82.
30. Oliphant A, Barker DL, Stuelpnagel JR, Chee MS. BeadArray technology: enabling an accurate, cost-effective approach to high-throughput genotyping. Biotechniques 2002;Suppl:56-8, 60-1.
31. van der Walt JM, Nicodemus KK, Martin ER, et al. Mitochondrial polymorphisms significantly reduce the risk of Parkinson disease. Am J Hum Genet 2003;72:804-11.
32. Schaid DJ, Rowland CM, Tines DE, Jacobson RM, Poland GA. Score tests for association between traits and haplotypes when linkage phase is ambiguous. Am J Hum Genet 2002;70:425-34.
33. Westfall P, Tobias R, Rom D, Wolfinger R, Hochberg Y. Multiple comparisons and multiple tests using SAS. Cary (NC): SAS Institute; 2004.
34. Martin TP, Irving RM, Maher ER. The genetics of paragangliomas: a review. Clin Otolaryngol 2007;32:7-11.
35. Gottlieb E, Tomlinson IP. Mitochondrial tumour suppressors: a genetic and biochemical update. Nat Rev Cancer 2005;5:857-66.
36. Franklin RB, Milon B, Feng P, Costello LC. Zinc and zinc transporters in normal prostate and the pathogenesis of prostate cancer. Front Biosci 2005;10:2230-9.
37. Berkun Y, Abou Atta I, Rubinow A, et al. 2756GG genotype of methionine synthase reductase gene is more prevalent in rheumatoid arthritis patients treated with methotrexate and is associated with methotrexate-induced nodulosis. J Rheumatol 2007;34:1664-9.
38. Urreizti R, Asteggiano C, Vilaseca MA, et al. A CBS haplotype and a polymorphism at the MSR gene are associated with cardiovascular disease in a Spanish case-control study. Clin Biochem 2007;40:864-8.
39. van Beynum IM, Kouwenberg M, Kapusta L, et al. MTRR 66A>G polymorphism in relation to congenital heart defects. Clin Chem Lab Med 2006;44:1317-23.
40. van der Linden IJ, den Heijer M, Afman LA, et al. The methionine synthase reductase 66A>G polymorphism is a maternal risk factor for spina bifida. J Mol Med 2006;84:1047-54.
41. Zhang Z, Shi Q, Liu Z, Sturgis E M, Spitz MR, Wei Q. Polymorphisms of methionine synthase and methionine synthase reductase and risk of squamous cell carcinoma of the head and neck: a case-control analysis. Cancer Epidemiol Biomarkers Prev 2005;14:1188-93.
42. Bosco P, Gueant-Rodriguez RM, Anello G, et al. Methionine synthase (MTR) 2756 (A -> G) polymorphism, double heterozygosity methionine synthase 2756 AG/methionine synthase reductase (MTRR) 66 AG, elevated homocysteinemia are three risk factors for having a child with Down syndrome. Am J Med Genet A 2003;121:219-24.